insights_auto
Why is AIM down ३.९५%?
Dive Deeperchevron_right
AIM:NYSEAMERICAN
AIM ImmunoTech Inc
US$ ०.१८
arrow_downward
-३.९५%(-०.००७५) 1D
US$ ०.१९
arrow_upward
+१.६४% (+०.००३०)bedtimeAfter hours
Closed: अक्टोबर ६, १६:००:०० GMT-४ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AIM...
Open
US$ ०.१९
High
US$ ०.१९
Low
US$ ०.१८
Mkt. cap
६८.९८ लाख
Avg. vol.
८७.४८ लाख
Volume
६.७३ लाख
52-wk high
US$ २.८८
52-wk low
US$ ०.१७
EPS
-US$ ३.९३
Beta
१.२७
Shares outstanding
३.९९ करोड
No. of employees
२०
Open
US$ ०.१९
High
US$ ०.१९
Low
US$ ०.१८
Mkt. cap
६८.९८ लाख
Avg. vol.
८७.४८ लाख
Volume
६.७३ लाख
52-wk high
US$ २.८८
52-wk low
US$ ०.१७
EPS
-US$ ३.९३
Beta
१.२७
Shares outstanding
३.९९ करोड
No. of employees
२०
News stories
From web sources and news partners
Stock Titan
·
१ दिन पहिले
An experimental antiviral draws attention for a possible role against Ebola
Profile
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
About AIM ImmunoTech Inc
CEO-
Employees२०
Founded१९६६
Headquartersफिलाडेल्फिया, पेन्सिलभेनिया, संयुक्त राज्य अमेरिका
Sector-
Websiteaimimmuno.com